An observational study in Gastric Reflux, sponsored by Zulekha Hospitals. Completed at 1 site in Egypt. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-11-13.
Sponsored by Zulekha Hospitals · Observational
A study comparing the effect of two doses of neostigmine on the gastric residual volume in critically ill patients on enteral feeding.
Participants were categorized into three groups: Group I and Group II received neostigmine 1 mg and 2 mg, respectively, and a control group received 10 ml of normal saline. All participants received an intravenous administration of 10 mg of metoclopramide. GRV was measured every 3 hours before enteral feeding. aspiration through nasogastric (NG) or orogastric (OG) tubes was done before the next due bolus of feeding.
1,086 studies on the registry are indexed under Gastroesophageal Reflux; 187 are open to participants now.
This study's enrollment of 3 is below the median of 175 across 304 observational studies indexed under Gastroesophageal Reflux.
Browse Gastroesophageal Reflux studies →Zulekha Hospitals is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study included 124 patients aged between 20 and 60 years requiring enteral feeding via nasogastric (NG) or orogastric (OG) tubes
Inclusion Criteria:
received neostigmine 1 mg
Drug: Neostigmine
received neostigmine 2 mg
Drug: Neostigmine
received normal saline
two groups (Group I, n= 41) and (Group II, n= 43) received varying doses of neostigmine (1 mg and 2 mg respectively
The risk of aspiration
The risk of aspiration in ICU patients on enteral feeding via vaso-gastric or oro-hastric tubes
Time frame: december 2022 to may 2024
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zulekha Hospitals